Federico Bolognani


Dr. Federico Bolognani is a Physician Scientist with more than 15 years of experience in Drug Development. He has a broad documented expertise in Basic and Translational Research in various settings, including Academic, Hospital, Biotechnology, Consultancy, Non-Profit Organizations, and Pharmaceutical Industry. He has worked in diverse fields such as Gene Therapy in the brain at the Molecular Medicine Unit, School of Medicine, University of Manchester, UK; Basic and Translational Neuroscience at the University of New Mexico School of Medicine, USA; and translational Neurooncology at the Department of Neurosurgery in the Methodist Hospital at the Texas Medical Center, Texas, USA. In 2009 he moved to Basel, Switzerland to work in the pharmaceutical industry at the Novartis Institutes of Biomedical Research (NIBR). Soon after, Dr. Bolognani joined the Neuroscience and Rare Disease division at Roche, where he led various Clinical Drug Development programs, with a focus on neurodevelopmental disorders, including Autism Spectrum Disorder. Since 2018, he has focused on the Biotechnology sector, developing drugs for Neuroscience and Rare disorders (Therachon, Axial Therapeutics, VectivBio). In these companies, as Head of Clinical Development, he led clinical programs that successfully delivered clinical trial results. Two of these companies were acquired by larger pharmaceutical entities. He is also a member of the Scientific Board of diverse Patient Advocacy groups and Foundations in Neurodevelopmental disorders. Dr. Bolognani has a track record of positive Clinical Trials in all Phases, from Phase 1 healthy volunteer trials, Phase 2 trials, to Phase 3 Pivotal trials. He has published more than 50 scientific papers in peer reviewed journals such as Nature Medicine, Science Translational Medicine, Journal of Neuroscience, Autism, Autism Research, Molecular Psychiatry, Biological Psychiatry, amongst others. He performed his studies at the Medical School of the National University of La Plata in Argentina where he obtained his MD and PhD degrees.